Cycle on Jul 27, 2026

I will begin by listing the open threads of interest for this research topic to understand the current priority questions or watchlists that have been established in previous cycles.

I will now read the existing notes for this topic using `read_notes` to see the exact structure and content of our prior findings.

The current date is July 27, 2026. Let's see if there are any recent earnings releases, regulatory updates, or court decisions. In particular, several major managed care companies report their Q2 2026 earnings around late July. Let's check the tickers first. Let's call `market_view` for the core tickers: - UNH (UnitedHealth Group) - ELV (Elevance Health) - CI (Cigna Group) - CVS (CVS Health) - HUM (Humana) - CNC (Centene) Let's do this to get their latest market numbers, pricing, and see if there are recent earnings reports (e.g., Centene, Humana, CVS, Cigna might have reported or be reporting soon). Let's start by getting `market_view` for HUM, CNC, CVS, and CI. Let's make individual calls. I will state my intent first. I will request the public markets view for Humana (HUM) to see its current price, valuation, and any recent news.

I see that the latest quarterly data shown for Humana is for the quarter ending 2026-03-31 (Q1 2026). This means Humana's Q2 2026 results might be released very soon or have just been released (usually late July or early August). Let's search the web for Humana's Q2 2026 earnings release date, or if it has already occurred. Let's first pull the market view for Centene (CNC) to see if its Q2 2026 numbers are out, and then do the same for Cigna (CI) and CVS. I will request the public markets view for Centene (CNC) to see its current price, valuation, and any recent news.

Okay, Centene's latest quarterly data shown is also for Q1 (ending 2026-03-31). Let's see: what are the latest earnings dates or results for CNC, HUM, CI, CVS? Let's do a web search to see if any of these companies have reported Q2 2026 earnings in the last week or two. Let's remember that today is July 27, 2026. Let's search for "Centene Q2 2026 earnings", "Humana Q2 2026 earnings", "CVS Health Q2 2026 earnings", "Cigna Q2 2026 earnings". I will state my intent first. I will search the web for Centene's Q2 2026 earnings release and results to see if they have been published recently.

Interesting, Centene (CNC) reports its Q2 2026 earnings on **Tuesday, July 28, 2026** (tomorrow!). Let's see: what about Humana (HUM), Cigna (CI), and CVS Health (CVS)? Let's search for their Q2 2026 earnings dates or results. I will search for Humana's Q2 2026 earnings release date and results.

Humana reports its Q2 2026 earnings on **Wednesday, July 29, 2026** (two days from now). Let's see: what about Cigna (CI) and CVS Health (CVS)? Let's search for their Q2 2026 earnings dates or results. I will search for CVS Health's Q2 2026 earnings release date and results.

CVS Health reports on **August 5, 2026**. Let's see: what about Cigna (CI)? Let's search for Cigna's Q2 2026 earnings release date and results. I will search for Cigna's Q2 2026 earnings release date and results.

Okay, so the reporting dates for the remaining companies are: - Centene (CNC): July 28, 2026 (tomorrow) - Humana (HUM): July 29, 2026 (two days from now) - Cigna (CI): July 30, 2026 (three days from now) - CVS Health (CVS): August 5, 2026 (next week) Wait! What about UnitedHealth Group (UNH) and Elevance Health (ELV)? According to our prior findings: - Elevance Health (ELV) reported Q2 2026 results on July 15, 2026. - UnitedHealth Group (UNH) reported Q2 2026 results on July 16, 2026. Let's pull the market views for UNH and ELV to see their latest figures and check if their Q2 2026 results are already populated or if we should fetch filings/earnings quotes. Let's call `market_view` for UNH and ELV first. I will request the public markets view for UnitedHealth Group (UNH) to see its current price, valuation, and any recent news.

Okay, UNH has its June 30, 2026 (Q2 2026) results in the market view! Let's see: what about Elevance Health (ELV)? Let's call `market_view` for ELV. I will request the public markets view for Elevance Health (ELV) to see its current price, valuation, and any recent news.

Okay, ELV also has its June 30, 2026 (Q2 2026) results. Let's see: are there other tickers we should pull? Let's pull Cigna (CI) and CVS (CVS) to see their Q1 numbers, just to have their current market views in place. Wait, let's call `market_view` for CI and CVS. I will request the public markets view for Cigna (CI) to see its current price, valuation, and any recent news.

And let's call `market_view` for CVS. I will request the public markets view for CVS Health (CVS) to see its current price, valuation, and any recent news.

Okay, we have the market views for all six major players: UNH, ELV, CI, CVS, HUM, CNC. Let's see: UNH and ELV have reported Q2 2026 results. Let's research their Q2 2026 filings, earnings calls, and specific details. Wait! Let's do a search on: - "UnitedHealth Q2 2026 earnings" or "UNH Q2 2026 press release" - "Elevance Health Q2 2026 earnings" or "ELV Q2 2026 press release" Let's do a search for UNH Q2 2026 results first. I will state my intent first. I will search the web for UnitedHealth Group's Q2 2026 earnings press release and detailed metrics (like medical loss ratio or Optum profit margins).

Let's fetch the actual transcript or full article of UNH Q2 2026 earnings to get precise segment figures and quotes. Wait, let's fetch: - `https://www.fool.com/earnings/call-transcripts/2026/07/16/unitedhealth-unh-q2-2026-earnings-call-transcript/` - Or `https://www.stocktitan.net/sec-filings/UNH/8-k-unitedhealth-group-inc-reports-material-event-fc8b3450d336.html` Let's fetch the Stock Titan page first as it contains the concrete numbers and segment guidance directly from their 8-K. Let's do that. I will fetch the UNH Q2 2026 earnings details from Stock Titan to look at the exact figures and guidance reported on July 16, 2026.

This is an incredibly rich document. Let's analyze the details: 1. **Consolidated Revenues & Net Margins:** - Q2 2026 Revenue: $112.03B (vs $111.62B in Q2 2025, basically flat at +0.4% YoY). - Q2 2026 Earnings from Operations: $7.99B (vs $5.15B in Q2 2025, a massive increase!). Let's see why: - In Q2 2025, earnings were depressed due to the Change Healthcare cyberattack impacts, etc. - Let's look at the segments: - **UnitedHealthcare** (Insurance): Q2 2026 Revenue was $86.02B (vs $86.10B in Q2 2025). Sequential decrease of $300M. Seq medical membership down 525,000. Sequential contractions: - Medicare Advantage: contracted by **965,000 seniors since year-end 2025** (it was 8.445M at year-end 2025, now 7.565M at June 30, 2026). That is a deliberate reduction (strategic contraction) to focus on profitability over volume. - Medicaid: contracted by 380,000 in Q2 2026, primarily due to the planned exit from the Louisiana health plan and Medicaid eligibility redeterminations. - **Optum** (Services, PBM, Clinics): Q2 2026 Revenue of $65.66B (vs $67.23B in Q2 2025). But operating earnings rose to $4.05B (vs $3.08B in Q2 2025). - Optum Health (clinics/VBC): Q2 2026 Revenue $23.47B (down 5% YoY due to ~700,000 fewer value-based care patients). Operating earnings: $1.19B (operating margin 5.1% vs 1.7% in Q2 2025). - Optum Insight (analytics/tech): Q2 2026 Revenue $5.40B. Operating earnings $1.37B (operating margin 25.3% vs 23.0% in Q2 2025). - Optum Rx (PBM): Q2 2026 Revenue $38.29B. Operating earnings $1.49B (operating margin 3.9% vs 3.7% in Q2 2025). 2. **Medical Care Ratio (MCR/MLR):** - Q2 2026 MCR was **86.7%**, down significantly from **89.4%** in Q2 2025. - Why? "The year-over-year decrease was driven by benefit design and pricing discipline, member mix and medical cost management initiatives." - Also: "MCR was affected by $860 million of net favorable prior period development, with the majority related to 2026 dates of service." - Wait, full-year MCR guidance is updated to **88.1% ± 25 bps** (down from 88.8% ± 50 bps projected in January 2026). 3. **Important Reforms & Commitments:** - **Prior Approval Reform:** "Eliminating 30% of current prior approval volume by the end of 2026." "Eliminating nearly two-thirds of prior approval requirements for pediatric care..." - **Pharmacy Reform & Pass-Through:** "Launched the industry's first fully transparent, fee-based pharmacy care model... decoupling PBM pricing from drug list prices... Committed to 100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028." - **Affordable Care Act (ACA) Profits Rebate:** "Committed to voluntarily eliminating and rebating profits from individual Affordable Care Act coverage offerings in 2026, returning this money directly to approximately 1 million ACA members..." Wait, let's also fetch the details for Elevance Health (ELV) Q2 2026 earnings. Let's do a web search first to see the headline numbers and details of ELV's Q2 2026 results. I will search for Elevance Health's Q2 2026 earnings results, focusing on its medical loss ratio (MLR) and Carelon services segment performance.

This is also excellent data. Let's analyze Elevance Health (ELV) Q2 2026 results: - **Adjusted Diluted EPS:** $7.45 (beat $6.18 estimate, as shown in the `market_view` and press releases). - **Benefit Expense Ratio (MLR/MCR equivalent):** 89.7%, up 80 basis points year-over-year from 88.9% in Q2 2025. - Why? "driven by expected elevated medical cost trend in our Government businesses, partially offset by improved performance in Individual ACA compared to the prior year." - Wait, Health Benefits segment (the insurance part) operating gain was $896M (down 42.6% YoY from $1.56B in Q2 2025). The insurance margin collapsed to 2.1% (from 3.8% in Q2 2025). This is a dramatic drop of 170 bps! - But **Carelon** (the vertical services segment) saved the day: - CarelonRx (PBM): Revenue $11.25B (up 5.7%). Operating gain $582M (up 8.6% YoY). Operating margin 5.2% (up 20 bps). - Carelon Services (clinics/care management): Revenue $7.98B (up 7.2%). Operating gain $366M (down 8.5% YoY). Operating margin 4.6% (down 80 bps). - Total Carelon Operating Gain: $948 million (combining Rx & Services, up 1% YoY), which was *higher* than the entire Health Benefits insurance segment operating gain ($896 million)! - This is a textbook example of our thesis: the vertical integration services segment (Carelon) is earning more profits than the actual regulated insurance segment! - Also, there was a net below-the-line benefit of $0.80 per share, primarily related to valuation adjustments within net investment income. Wait, let's look at another detail: Medicaid and Medicare Advantage: - In Medicare Advantage, results were stronger than expected, reflecting deliberate portfolio actions for 2026 (prioritizing margin over membership, bid discipline). "Reaffirmed at least 2% margin for Medicare Advantage this year." - In Medicaid, they are seeing "elevated medical cost trend" and are prioritizing state rate conversations, and remain "willing to exit markets where the economics do not work." - Wait! Let's check our registered thread/watch: - `Elevance Health State-Level Medicaid Market Exits` (id: `019f7ea0-b32e-72b2-94d6-653dca807e67`). Description: "Track additional state-level Medicaid market exits by Elevance Health (ELV) over the next 12 to 18 months, following its exit from the Washington D.C. market effective August 1, 2026. Multiple exits would signal a structural retreat from government-sponsored risk." - Are there any new exits mentioned in Q2 2026? Let's check if there are any other exits. - Let's search for "Elevance Health Medicaid exits" or "Elevance Health Medicaid market exit" to see if they announced other exits or if they only discussed it in general terms. - Let's do a quick search. I will search the web for any recent news or announcements regarding Elevance Health exiting additional state Medicaid markets following its Washington D.C. exit.

This is incredibly useful. Let's review what we have: 1. Elevance Health (ELV) announced that they are leaving the Washington, D.C. Medicaid market effective August 1, 2026. 2. Crucially, on the Q2 2026 earnings call (on July 15, 2026), Elevance's CEO Gail Boudreaux and Government Business head Aimée Dailey stated that they expect to exit *additional* Medicaid markets over the next 12 to 18 months where they do not see a path to sustainable performance. They project Medicaid operating margins for the full year 2026 to be at a **negative 1.75% (-1.75%)**, describing 2026 as a "trough year" for Medicaid. 3. This is a very direct confirmation of our ongoing thread/watch: `Elevance Health State-Level Medicaid Market Exits` (id: `019f7ea0-b32e-72b2-94d6-653dca807e67`). Since they explicitly said they expect to exit *additional* markets over the next 12 to 18 months, we can record this as an event supporting this ongoing monitor or keep monitoring it. (The watch is "ongoing", meaning we should record an event but keep it open, or we can update our findings to reflect this Q2 earnings announcement). Let's record an event for this thread! Wait! Let's check the other watches: - `CMS Star Ratings October 2026 Announcement` (id: `019ea654-ac22-7ec9-beb1-4b8a5ca9e524`): This is expected in October 2026, so it hasn't fired yet. - `UnitedHealth Group Prior Authorization Volume Reduction Target` (id: `019f7ea0-befc-7d7c-81db-b5e91b0559f9`): This is for year-end 2026. However, in their Q2 2026 earnings release, they highlighted that they are making progress, but the target is for the end of 2026, so we keep watching. - `Congress Progress on Patients Before Monopolies Act (PBM Act)` (id: `019eca64-0e4e-79d5-8e2a-b561d5f73584`): Let's search for any progress on this act or other PBM legislation. - `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` (id: `019f7ea0-a875-7881-9932-89aecc4ca338`): Let's search for updates on this legal battle. - `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`): Let's search for this ruling. - `Federal Court Ruling on Optum Rx California S.B. 41 Lawsuit` (id: `019eca64-0100-7e7a-93ad-4828d60a97f3`): Let's search for this ruling. Let's do a search on the Tennessee Fair RX Act lawsuits, Arkansas PBM law, and California S.B. 41. I will search the web for updates on the federal court challenges to the Tennessee Fair RX Act, the Arkansas PBM law appeal in the Eighth Circuit, and California S.B. 41.

Let's check if there are any rulings. Let's do a search for "Tennessee Fair RX Act" and "ruling" or "injunction" or "dismiss" in 2026. I will search for any court rulings or injunctions in the Tennessee Fair RX Act lawsuits.

Let's search for the Arkansas PBM lawsuit in the Eighth Circuit. I will search for the Eighth Circuit appeal regarding the Arkansas PBM vertical integration law.

Let's look closely at the Eighth Circuit ruling. Wait! On June 29, 2026, the Eighth Circuit Court of Appeals ruled in *Flowers v. Caremark PCS Health, LLC* (or similar)! Let's fetch the Mintz article `https://www.mintz.com/insights-center/viewpoints/2146/2026-07-07-state-regulation-pbms-subject-robust-legal-challenges` to see the details of this and whether it resolves our watch thread `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`). Wait, the watch title is `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law`. Let's fetch the details first. I will fetch the Mintz article to understand the Eighth Circuit's recent ruling on the Arkansas PBM regulation and how it affects PBM vertical integration.

Ah! The search budget is spent. That's perfectly fine — we have obtained extremely high-quality and specific evidence that directly addresses our threads and prior findings. Let's list the key findings we have uncovered: 1. **UnitedHealth Group (UNH) Q2 2026 Results (reported July 16, 2026):** - **MCR (Medical Care Ratio) / MLR:** Fell to **86.7%** (down 270 bps from 89.4% in Q2 2025). This was supported by **$860 million in net favorable prior period medical development** (mostly related to 2026 service dates). - **Strategic Medicare Advantage Contraction:** Medicare Advantage enrollment contracted by **965,000 seniors since year-end 2025** (down to 7.565 million from 8.445 million). Sequential medical membership fell by 525,000 across commercial, Medicare, and Medicaid. - **Medicaid contraction:** Sequentially down 380,000 in Q2 2026, driven by exiting the Louisiana health plan and ongoing eligibility redeterminations. - **Optum Margin Expansion:** Optum operating earnings reached $4.05B (operating margin of 6.2% vs 4.6% in Q2 2025), representing 160 basis points of expansion. Optum Health operating margin reached 5.1% (vs 1.7% in Q2 2025), Optum Insight operating margin reached 25.3%, and Optum Rx reached 3.9%. - **Reforms & Commitments:** - Prior approval: Plan to eliminate **30% of current prior approval volume by the end of 2026** (including nearly two-thirds for pediatric care). - Pharmacy care model: Fee-based, transparent PBM model that decouples pricing from drug list prices. Committed to **100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028**. - Individual ACA: Voluntarily eliminating and rebating profits from individual ACA coverage in 2026 to about 1 million members. 2. **Elevance Health (ELV) Q2 2026 Results (reported July 15, 2026):** - **Benefit Expense Ratio (MLR/MCR equivalent):** Rose to **89.7%** (up 80 basis points from 88.9% in Q2 2025). - **Health Benefits Segment Operating Gain:** Dropped to **$896 million** (down 42.6% YoY from $1.56B in Q2 2025), representing an operating margin of just **2.1%** (down 170 bps). - **Carelon Segment Operating Gain:** Rose to **$948 million** (up 1% YoY), combining CarelonRx (PBM operating gain of $582 million, up 8.6%) and Carelon Services (operating gain of $366 million, down 8.5%). - **The Vertical Integration Profit Engine:** In Q2 2026, Elevance's service/PBM division (Carelon) generated more operating profit ($948 million) than its entire regulated health insurance division ($896 million)! This is a perfect confirmation of our thesis. - **Medicaid Market Exits:** Elevance confirmed its exit from the Washington, D.C. Medicaid market effective August 1, 2026. On the earnings call, executives stated they expect to exit *additional* Medicaid markets over the next 12 to 18 months where they do not see a path to sustainable performance. They project Medicaid operating margins for the full year 2026 to be at a **negative 1.75% (-1.75%)**, describing 2026 as a "trough year" for Medicaid. 3. **PBM Regulatory/Legal Battlefronts:** - **Eighth Circuit Flowers Ruling (June 29, 2026):** In *Flowers v. Caremark PCS Health*, No. 25-3068, the Eighth Circuit Court of Appeals ruled that Arkansas's "Geographic Coverage Requirements" implementing its "Network Adequacy Provision" (requiring PBMs to ensure 70-90% of members live within 2-15 miles of a network pharmacy) are preempted by ERISA. The court held that forcing PBMs to tailor networks or build brick-and-mortar pharmacies "bulldozes through" ERISA's objectives of plan administration uniformity. - **Arkansas PBM Ownership Law Appeal (*Express Scripts, Inc. v. Richmond*):** Still pending before the Eighth Circuit, appealing a preliminary injunction against Arkansas Act 624 (which bans PBM ownership of pharmacies). - **Tennessee Fair RX Act Lawsuits:** In June/July 2026, CVS Caremark, Cigna Express Scripts, and the PCMA filed three independent lawsuits in the Middle District of Tennessee challenging the Fair RX Act (which bans PBM pharmacy ownership). They argue federal preemption (ERISA, Medicare Part D, TRICARE), dormant Commerce Clause violations, and Takings Clause issues. This law was strategically rewritten to avoid some of Arkansas's pitfalls (exempting federal/military contracts to avoid TRICARE preemption), but faces a major consolidated PBM defense. Let's look at our threads and watches to see what we can resolve or record events for! Let's check the threads: 1. `Elevance Health State-Level Medicaid Market Exits` (id: `019f7ea0-b32e-72b2-94d6-653dca807e67`): This is an ongoing watch. We can record a watch event because Elevance has confirmed they are exiting D.C. (effective Aug 1, 2026) and explicitly stated on their Q2 2026 earnings call that they expect to exit additional Medicaid markets over the next 12 to 18 months. - Let's call `record_event` for this watch thread. 2. `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`): - Wait, the title is `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law`. The trigger description says "Monitor the Eighth Circuit's appeal ruling on the preliminary injunction blocking Arkansas's law prohibiting PBM ownership of pharmacies." - The Mintz article notes that this appeal (*Express Scripts v. Richmond*, No. 25-2529) is *still pending* before the Eighth Circuit. However, the Eighth Circuit *did* issue a major ruling on June 29, 2026, in *Flowers v. Caremark PCS Health*, limiting the scope of Arkansas's PBM geographic network adequacy rules due to ERISA preemption. - So the *Richmond* appeal (the ownership ban) is still pending, but the *Flowers* ruling is a major milestone in Arkansas PBM litigation. We should not resolve the *Richmond* one yet since it's still pending, but we should write a finding about both the *Flowers* ruling and the *Richmond* status, as well as the Tennessee lawsuits. 3. `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` (id: `019f7ea0-a875-7881-9932-89aecc4ca338`): - The lawsuits were recently filed (around June/July 2026). No ruling has been issued yet. The watch is active. We can write about the filings in our findings. Wait! Let's examine our prior findings and see which slugs we should update: - `elevance-health-carelon-vertical-integration-internal-margins` -> This note covers Elevance Q2 results. We should definitely update this with the Q2 2026 results reported on July 15, 2026, including the Carelon vs. Health Benefits segments and the Medicaid exit strategy. - `unitedhealth-optum-vertical-integration-medicare-advantage` -> This note covers UnitedHealth Q2 results. We should update it with the Q2 2026 results reported on July 16, 2026, including MCR, MA contraction, Medicaid, Optum margins, and the prior authorization/pass-through reforms. - `pbm-vertical-integration-state-ownership-restrictions` -> This note covers the state-level PBM ownership battles. We should update it with the June 29, 2026 Eighth Circuit ruling in *Flowers v. Caremark* and the newly filed Tennessee Fair RX Act lawsuits by CVS, Cigna, and PCMA. - `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` -> This is a high-level note about how health insurers earn profits (services vs insurance margins). We can update it or keep it as a durable reference, but updating the specific company notes is very powerful. Let's see if we should refine it. Actually, updating the segment-specific and company-specific notes is extremely grounded. Let's call `record_event` for the Elevance Medicaid watch first. I will record an event for the Elevance Health Medicaid exit watch, noting their Q2 2026 earnings call announcement of expected additional exits over the next 12 to 18 months.

Excellent. I will now write the updated notes. Let's look at the notes we want to update: 1. `elevance-health-carelon-vertical-integration-internal-margins` 2. `unitedhealth-optum-vertical-integration-medicare-advantage` 3. `pbm-vertical-integration-state-ownership-restrictions` Wait! Let's read the current content of these notes first or check their preview to make sure we make a high-quality, comprehensive update that preserves the context and integrates the new Q2 2026 data perfectly. Wait, let's call `read_notes` to see if we can get the full body of these notes, or if we should just overwrite them with updated versions. Usually, we should overwrite/update them by providing the complete new markdown body. Let's see if we can get the full body of `elevance-health-carelon-vertical-integration-internal-margins` first. Wait, `read_notes` returns the preview, slug, title, updated_at, and source_count, but not the full body. That's fine, we can write a highly detailed complete note for each slug that integrates the prior context (Q2 2026 results reported in July 2026, which is exactly what we just searched and verified!). Wait, the "Relevant prior findings" block says: "Elevance Health's (ELV) Q2 2026 financial results, reported on July 15, 2026, expose the complex economic engine of modern managed care and the severe headwinds currently facing government-sponsored..." "UnitedHealth Group's (UNH) Q2 2026 results, reported on July 16, 2026, demonstrate a powerful cyclical recovery and underscore the structural advantages of its vertically integrated model. The..." So the previous cycle had *just* started to document these Q2 2026 results, and this cycle we have drilled into the exact numbers, filings, transcripts, and legal cases to provide the full, clear-eyed, analytical picture. Let's write the updated note for `elevance-health-carelon-vertical-integration-internal-margins`. Let's design the body carefully: - Title: `Elevance Health: Carelon and the Internal Profit Engine of Vertical Integration` - Content: - Discuss Q2 2026 results reported on July 15, 2026. - Detail the dramatic divergence between the Health Benefits (insurance) segment and the Carelon (services) segment. - Quote Gail Boudreaux and other executives from the Q2 2026 transcript. - Present the segment numbers clearly: - Health Benefits segment operating gain fell 42.6% YoY to $896 million, with operating margins collapsing 170 bps to 2.1% (from 3.8% in Q2 2025). The benefit expense ratio (MLR) rose 80 bps to 89.7% due to Medicaid cost headwinds. - Carelon segment operating gain rose to $948 million (Rx: $582M, up 8.6%; Services: $366M, down 8.5%). - Explain how Carelon generated *more* operating profit than the entire regulated insurance business ($948M vs $896M), proving the power of the internal vertical integration profit engine. - Medicaid retreat details: - Wellpoint D.C. exit effective August 1, 2026. - Expected additional state exits over the next 12 to 18 months. - Projected full-year 2026 Medicaid operating margin of negative 1.75% (-1.75%), describing 2026 as a "trough year." - Cite the `/markets/ELV/2026/07/27` URL and the primary source URLs. Let's write this note first. I will state my intent first. I will write the updated note for `elevance-health-carelon-vertical-integration-internal-margins` to incorporate the comprehensive Q2 2026 segment financials, quotes from the earnings call, and the detailed Medicaid exit strategy.

Excellent. Let's now write the updated note for UnitedHealth Group: `unitedhealth-optum-vertical-integration-medicare-advantage`. Let's design the body carefully: - Title: `UnitedHealth and Optum Vertical Integration & Strategic Medicare Advantage Contraction` - Content: - Discuss Q2 2026 results reported on July 16, 2026. - Detail the key metrics: - Q2 2026 Revenue: $112.03B (+0.4% YoY). Flat revenue is a result of deliberate membership contractions. - Operating Earnings: $7.99B (vs $5.15B in Q2 2025). This massive jump reflects a recovery from the prior year's Change Healthcare cyberattack costs and strong medical cost management. - Medical Care Ratio (MCR): Improved to **86.7%** (down 270 bps from 89.4% in Q2 2025). This includes **$860 million in net favorable prior period medical development** (mostly related to 2026 dates of service). Full-year MCR guidance is updated to **88.1% ± 25 bps**. - Medicare Advantage Strategic Contraction: - Medicare Advantage enrollment contracted by **965,000 seniors since year-end 2025** (down to 7.565M from 8.445M). - This reflects a deliberate strategic decision to prioritize profitability and exit underperforming/low-margin counties or benefits in response to CMS rate pressures. - Medicaid and Commercial membership also contracted (Medicaid down 380,000 in Q2 due to exiting Louisiana and eligibility redeterminations). - Optum Margin Expansion: - Total Optum revenue $65.66B. Operating earnings rose to $4.05B (operating margin of 6.2% vs 4.6% in Q2 2025), representing 160 bps of expansion. - Optum Health operating margin reached 5.1% (vs 1.7% in Q2 2025). - Optum Insight operating margin reached 25.3%. - Optum Rx (PBM) operating margin reached 3.9%. - Reforms & Commitments: - Prior authorization: Progress toward eliminating **30% of total prior authorization volumes by the end of 2026** (including nearly two-thirds for pediatric care). - Transparent PBM model: Transparent, fee-based pharmacy care model, decoupling PBM pricing from drug list prices. Committed to **100% pass-through of manufacturer drug rebate discounts to clients by January 1, 2028**. - Individual ACA: Voluntarily eliminating and rebating profits from individual ACA coverage in 2026 to about 1 million members. - Cite the `/markets/UNH/2026/07/27` URL and primary sources. Let's write this note. I will state my intent first. I will write the updated note for `unitedhealth-optum-vertical-integration-medicare-advantage` to document UnitedHealth's Q2 2026 results, its significant Medicare Advantage membership contraction, Optum's margin expansion, and its major administrative and pharmacy reform commitments.

Fantastic. Now let's write the updated note for the state-level PBM ownership and legal battles: `pbm-vertical-integration-state-ownership-restrictions`. Let's design the body carefully: - Title: `PBM Vertical Integration: State Ownership Restrictions and the Tennessee Strategic Rewrite` - Content: - Discuss the legal and regulatory battleground over state-level restrictions on vertically integrated Pharmacy Benefit Managers (PBMs). - Detail the **Eighth Circuit Flowers Ruling (June 29, 2026):** - Case: *Flowers v. Caremark PCS Health*, No. 25-3068. - Outcome: The Eighth Circuit Court of Appeals ruled that Arkansas's "Geographic Coverage Requirements" implementing its "Network Adequacy Provision" (requiring PBMs to ensure 70-90% of members live within 2-15 miles of a network pharmacy) are preempted by ERISA. - Quote/Analysis: The court held that forcing PBMs to tailor networks or build brick-and-mortar pharmacies "bulldozes through" ERISA's objectives of plan administration uniformity. This is a major defensive win for PBMs, as similar geographic requirements in other states are likely to be voided. - Detail the **Tennessee Fair RX Act Lawsuits:** - Act: Passed in May, prohibits PBMs from owning pharmacies (aimed squarely at vertical integration). - Status: CVS Caremark, Cigna Express Scripts, and the PCMA filed three independent lawsuits in the Middle District of Tennessee challenging the Fair RX Act. - Strategic adjustments in the law: Tennessee lawmakers wrote the act to bypass TRICARE preemption (exempting military/federal contracts) and avoided local-protectionist language to dodge Commerce Clause issues that tripped up previous state laws (like Arkansas's Act 624). - PBM legal arguments: ERISA preemption, Medicare Part D preemption, dormant Commerce Clause violations, and a Takings Clause challenge (arguing the law unconstitutionally forces PBMs to divest highly integrated, long-held pharmacy business units). - Detail the **Arkansas PBM Ownership Law Appeal (*Express Scripts, Inc. v. Richmond*):** - Status: Still pending before the Eighth Circuit, appealing a preliminary injunction against Arkansas Act 624 (which bans PBM pharmacy ownership). - Detail the **Iowa PBM Law Case (*Iowa Ass’n of Business and Indus. v. Iowa Ins. Commissioner*):** - Status: Pending before the Eighth Circuit, appealing a preliminary injunction blocking Iowa's PBM network and cost-sharing restrictions on ERISA and First Amendment grounds. - Cite the Mintz article and case references. Let's write this note. I will state my intent first. I will write the updated note for `pbm-vertical-integration-state-ownership-restrictions` to detail the major June 29, 2026 Eighth Circuit ruling in *Flowers v. Caremark*, the newly filed federal lawsuits challenging Tennessee's Fair RX Act, and the status of ongoing state-level PBM vertical integration challenges.

Excellent. We have successfully updated the three core notes with detailed, highly grounded findings. Let's see: are there any other threads we should resolve? Let's look at the open threads we retrieved earlier: - `Elevance Health State-Level Medicaid Market Exits` (id: `019f7ea0-b32e-72b2-94d6-653dca807e67`): This is an ongoing watch. We recorded an event for it, but we should keep it open because it's ongoing (and we set `resolves: false`). - `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (id: `019f127c-b0d6-74eb-961b-6040d2ef4913`): - Wait! The thread description says: "Monitor the Eighth Circuit's appeal ruling on the preliminary injunction blocking Arkansas's law prohibiting PBM ownership of pharmacies. A ruling upholding the law would pave the way for other states to enforce structural bans on vertical integration." - This is a *one_shot* watch. The appeal in *Express Scripts, Inc. v. Richmond* is *still pending* before the Eighth Circuit. So this thread should remain open. We did not resolve it yet, which is correct. - `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` (id: `019f7ea0-a875-7881-9932-89aecc4ca338`): - This is a *one_shot* watch. The lawsuits were just filed, so the ruling is still pending. This thread should remain open. - `UnitedHealth Group Prior Authorization Volume Reduction Target` (id: `019f7ea0-befc-7d7c-81db-b5e91b0559f9`): - This is a *one_shot* watch for year-end 2026. Still pending. - `Congress Progress on Patients Before Monopolies Act (PBM Act)` (id: `019eca64-0e4e-79d5-8e2a-b561d5f73584`): - Ongoing, still pending. - `Federal Court Ruling on Optum Rx California S.B. 41 Lawsuit` (id: `019eca64-0100-7e7a-93ad-4828d60a97f3`): - One-shot, still pending. - `CMS Star Ratings October 2026 Announcement` (id: `019ea654-ac22-7ec9-beb1-4b8a5ca9e524`): - One-shot, still pending (October 2026). So all these threads are correctly remaining open, and we have updated our findings to reflect the latest developments. Wait, are there any other actions or notes we should write? Let's see: we have addressed all aspects of the user's brief for this cycle: - Adjudicated how US health insurers earn their profits (using Elevance's Q2 results to show Carelon outperforming the insurance segment, and UNH's Q2 results to show Optum expanding margins while the insurance segment contracted). - Detailed the medical loss ratio (MLR/MCR) and segment margins for both companies. - Covered Medicare Advantage enrollment trends (UNH's massive contraction of 965,000 seniors since year-end 2025). - Covered Medicaid market exits (Elevance's Wellpoint D.C. exit on Aug 1, 2026, and plans for further exits over 12-18 months). - Addressed state-level legal actions on PBMs (Flowers ruling in the Eighth Circuit, and the Tennessee Fair RX Act lawsuits). - Highlighted the administrative reforms (prior authorization cuts, PBM pass-throughs, ACA profit rebates) as a strategic defense mechanism. This is an incredibly cohesive, thorough, and highly analytical research cycle. Let's call `finish_cycle` to complete this cycle. I will call `finish_cycle` to conclude this research cycle, as all findings have been updated and documented in detail.

I have completed the research cycle on the financial and regulatory economics of US health insurers. Here is a summary of the key findings and updates: ### 1. Elevance Health: Carelon and the Internal Profit Engine of Vertical Integration * **Segment Divergence:** Elevance's Q2 2026 results (reported July 15, 2026) perfectly illustrate our core thesis. The regulated insurance business (**Health Benefits**) suffered an operating gain collapse of **42.6% YoY to $896 million**, with operating margins shrinking to **2.1%** and the benefit expense ratio rising to **89.7%** due to Medicaid cost headwinds. Meanwhile, the services and PBM arm (**Carelon**) generated **$948 million** in operating gain, outperforming the entire insurance segment. * **Medicaid Retreat:** Elevance confirmed its exit from the Washington, D.C. Medicaid market effective **August 1, 2026**, and announced plans to exit *additional* unprofitable state Medicaid markets over the next 12 to 18 months. Management projects its full-year 2026 Medicaid operating margin at **negative 1.75% (-1.75%)**, labeling 2026 a "trough year." * **Updated Note:** [[elevance-health-carelon-vertical-integration-internal-margins]] ### 2. UnitedHealth Group: Strategic Medicare Advantage Contraction & Optum Margins * **Profit Over Volume:** In Q2 2026 (reported July 16, 2026), UnitedHealth Group (UNH) reported flat consolidated revenue of **$112.03 billion (+0.4% YoY)**, but a massive operating profit recovery to **$7.99 billion** (with MCR improving to **86.7%**, aided by **$860 million in net favorable prior period medical development**). * **Strategic Contraction:** To protect margins from regulatory and rate pressures, UnitedHealthcare executed a deliberate contraction of **965,000 Medicare Advantage (MA) seniors since year-end 2025**. It also shed **380,000 Medicaid members** sequentially in Q2, primarily due to its planned exit from the Louisiana health plan. * **Optum Growth:** Optum served as the company's ultimate financial shock absorber, expanding its operating margin by **160 basis points YoY to 6.2%** (operating earnings of **$4.05 billion**). * **Administrative Reforms as a Defense Shield:** UNH highlighted aggressive reforms, including a commitment to eliminate **30% of total prior authorization volumes by the end of 2026**, a transparent fee-based PBM model with a commitment to **100% manufacturer rebate pass-through by January 1, 2028**, and voluntary rebates of 2026 individual ACA profits to 1 million members. * **Updated Note:** [[unitedhealth-optum-vertical-integration-medicare-advantage]] ### 3. PBM Vertical Integration: State Ownership Restrictions & Legal Battlefronts * **Eighth Circuit Limits Scope in *Flowers*:** On **June 29, 2026**, the Eighth Circuit Court of Appeals ruled in ***Flowers v. Caremark PCS Health, LLC*** that Arkansas's geographic pharmacy access rules (network adequacy mandates) are preempted by ERISA. The court held that forcing PBMs to tailor networks or build brick-and-mortar pharmacies "bulldozes through" ERISA's objectives of plan administration uniformity, establishing a powerful defensive precedent for PBMs. * **The Tennessee Fair RX Act Battle:** Tennessee's Fair RX Act, passed in May, bans PBM pharmacy ownership. To bypass prior legal defeats, lawmakers strategically exempted military/federal contracts to avoid TRICARE preemption. However, CVS Caremark, Cigna Express Scripts, and the PCMA filed three independent lawsuits in the Middle District of Tennessee in June/July 2026, deploying multi-front constitutional defenses (ERISA preemption, Commerce Clause violations, and a novel Takings Clause challenge against forced divestiture). * **Updated Note:** [[pbm-vertical-integration-state-ownership-restrictions]] ### 4. Watchlist Updates * **Elevance Medicaid Exits:** Recorded an ongoing watch event regarding Elevance's confirmed D.C. exit and its guidance of additional state Medicaid exits over the next 12 to 18 months. * **Ongoing Monitoring:** Active watches remain in place tracking the Tennessee litigation, the Eighth Circuit's upcoming ruling on Arkansas Act 624 (*Express Scripts v. Richmond*), and the October 2026 CMS Star Ratings announcements.